Median length of orphan and non-orphan drugs in phase III trial 2015
Median phase III trial length for orphan and non-orphan drugs as of 2015 (in years)
This statistic displays the median length of time that orphan and non-orphan products are in phase III trial, as of 2015. Orphan drugs were in phase III trials for a median of 2.89 years. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Median phase III trial length for orphan and non-orphan drugs as of 2015 (in years)
Loading statistic...
| Median length of time in years | |
|---|---|
| Orphan | 2.89 |
| Non-orphan | 2.88 |
| All | 2.88 |
Source
More information
Statistics on "Pharmaceutical industry in the Netherlands"
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Required number of patients for phase III trials of orphan and non-orphan drugs 2015
- Number of cumulative orphan designations accepted in the U.S. 2003-2018
- Average FDA approved orphan drug sales U.S. 5 years after launch 2014
- Top new orphan molecular entities by U.S. sales in 2019
- Leading orphan designations in the EU by indication 2015
- Median length of time for orphan and non-orphan drugs for FDA approval 2015
- Orphan drug sales worldwide excluding oncology by therapy category 2024
- Orphan vs. non-orphan pipeline sales forecast worldwide 2019-2024
- Worldwide share of orphan drug sales by therapy category without oncology 2024
- Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Worldwide Rx drug sales excluding generics and orphan drugs 2002-2024
- Pricing of orphan drugs across three countries on annual basis 2016
- Utilization of orphan drugs in the U.S. by usage type 2014
- Utilization of orphan drugs in the U.S. from 2012 to 2014, by usage type
- Cumulative price change of orphan drugs in the U.S. 2012-2014
- Number of orphan drugs used in Norway 2016-2018
- U.S. orphan drugs with patents and orphan drug exclusivity as of 2018
- Impact of clinical trials on the daily lives of participants globally 2017
- U.S. orphan drugs with patents and orphan drug exclusivity as of 2018, by duration
- Ad spending for Amgen's top product Enbrel U.S. 2014-2015
Statistics on "Pharmaceutical industry in the Netherlands"
Related topics
About Statista
